Portal de Periódicos da CAPES

The Treatment of Gram-negative Bacillary Infections with Colistin

1962; American College of Physicians; Volume: 57; Issue: 2_Part_1 Linguagem: Inglês

10.7326/0003-4819-57-2-214

1539-3704

F. Robert Fekety,

Nephrotoxicity and Medicinal Plants

Article1 August 1962The Treatment of Gram-negative Bacillary Infections with ColistinThe Toxicity and Efficacy of Large Doses in Forty-eight PatientsF. ROBERT FEKETY JR., M.D., PHILIP S. NORMAN, M.D., LEIGHTON E. CLUFF, M.D.F. ROBERT FEKETY JR., M.D.Search for more papers by this author, PHILIP S. NORMAN, M.D.Search for more papers by this author, LEIGHTON E. CLUFF, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-57-2-214 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSepticemia and chronic urinary tract infections caused by Gram-negative bacilli rarely respond dramatically to antibacterial therapy. There are several reasons for this. First, and perhaps of paramount importance, is the clinical setting of impaired local or systemic resistance in which these infections usually occur. The appearance of infection in such patients is a signal that defense mechanisms vital to the control of organisms with little pathogenicity have been tested and found wanting. In these circumstances, only highly effective counter-measures will lead to a bactriologic cure. A second factor, then, is the relative insensitivity of these organisms to the commonly employed...References1. CARROLLMALETTE GWF: The use of colymycin in chronic urinary infections due to Pseudomonas aeruginosa. J. Urol. 85: 86, 1961. CrossrefMedlineGoogle Scholar2. HALL JW: Colistin. Analysis of a new antibiotic in 44 cases of systemic Gram-negative infection. Amer. J. Med. Set. 240: 561, 1960. CrossrefGoogle Scholar3. MCCABEJACKSON WRGG: Treatment of chronic pyelonephritis. III. Comparison of several drugs combined and one member of the combination, colistin. Amer. J. Med. Sci. 240: 754, 1960. CrossrefMedlineGoogle Scholar4. MCCABEJACKSONKOZIJ WRGGVM: Clinical and laboratory observations on the use of colistin in infections by Gram-negative bacilli, in Antibiotics Annual 1959-1960, Antibiotica, Inc., New York, 1960, p. 80. Google Scholar5. PETERSDORFHOOK RGEW: The use of colistin in the treatment of infections of the urinary tract. Bull. Johns Hopkins Hosp. 107: 133, 1960. MedlineGoogle Scholar6. ROBERTSKIRBY CEWM: Colistin in the treatment of hospitalized patients with pseudomonas infections, in Antimicrobial Agents Annual, Plenum Press, Inc., New York, 1961, p. 409. Google Scholar7. YOWTANSHANESCHONFELDABU-NASSAR EMELSH: Colistin in resistant bacterial infections. Arch. Intern. Med. 108: 664, 1961. CrossrefMedlineGoogle Scholar8. WRIGHTWELCH WWH: Chemical, biological, and clinical observations on colistin, in Antibiotics Annual 1959-1960, Antibiotica, Inc., New York, 1960, p. 61. Google Scholar9. SCHWARTZWARRENBARKLEYLANDIS BSMRFAL: Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate, in Antibiotics Annual 1959-1960, Antibiotica, Inc., New York, 1960, p. 41. Google Scholar10. POSTICFINLAND BM: In vitro susceptibility of recently isolated strains of Pseudomonas aeruginosa to ten antibiotics. Amer. J. Med. Sci. 242: 551, 1961. CrossrefMedlineGoogle Scholar11. HIRSCHMCCARTHYFINLAND HCCGM: Polymyxin B and colistin: activity, resistance and cross resistance in vitro. Proc. Soc. Exp. Biol. Med. 103: 338, 1960. CrossrefMedlineGoogle Scholar12. MELENEYPROUT FLGR: Some laboratory and clinical observations on coly-mycin with particular reference to pseudomonas infections. Surg. Gynec. Obstet. 112: 211, 1961. MedlineGoogle Scholar13. FEKETYCLUFF FRLE: Studies on the antibiotic therapy of serious staphylococcal infections. Ann. Intern. Med. 56: 198, 1962. LinkGoogle Scholar14. ROSSPUIGZAREMBA SJREA: Colistin: some preliminary laboratory and clinical observations in specific gastroenteritis in infants and children, in Antibiotics Annual 1959-1960, Antibiotica, Inc., New York, 1960, p. 89. Google Scholar15. GOODMANGILMAN LSA: The Pharmacological Basis of Therapeutics, 2d Ed., The Macmillan Company, New York, 1955, p. 1403. Google Scholar16. KUNINFINLAND CMM: Clinical pharmacology of the various tetracycline antibiotics. Clin. Pharmacol. Ther. 2: 51, 1961. CrossrefMedlineGoogle Scholar17. WHITEKNIGHT AV: Kanamycin: pharmacological microbiological and clinical observations. Ann. N. Y. Acad. Sci. 76: 277, 1958. CrossrefMedlineGoogle Scholar18. HERMAN LG: Antibiotic sensitivity testing using pretreated agar plates. III. In vitro inhibition of proteus species with a combination of sulfathiazole and colistimethate sodium. Paper presented at the First Interscience Conference on Antimicrobial Agents and Chemotherapy, October 31-November 2, 1961, sponsored by the American Society for Microbiology, New York, New York. Google Scholar19. MOYERMILLSYOW JHLCEF: Toxicity of polymyxin B. Arch. Intern. Med. 92: 238, 1953. CrossrefGoogle Scholar20. MOHANPIANOTTI RRRS: Studies on the mode of action of colistin sulfate on Pseudomonas aeruginosa, in Bacteriological Proceedings 1960, Society of American Bacteriologists, Waverly Press, Baltimore, p. 99. Google Scholar21. NEWTON BA: The properties and mode of action of the polymyxins. Bact. Rev. 20: 14, 1956. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Supported by a grant from the Warner-Lambert Research Institute, Morris Plains, New Jersey; and in part by a contract between the United States Army Chemical Corps, Fort Detrick, Frederick, Maryland, and the Johns Hopkins University School of Medicine, Baltimore, Maryland; and by training grant 2E-9, National Institutes of Health, Bethesda, Maryland.Dr. Norman is a career research development awardee, National Institute of Allergy and Infectious Diseases, United States Public Health Service.Requests for reprints should be addressed to F. Robert Fekety, M.D., Department of Medicine, The Johns Hopkins Hospital, 601 North Broadway, Baltimore 5, Maryland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPolymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomesOccurrence of mcr Positive Strains and Molecular Characteristics of Two mcr-1 Positive Salmonella typhimurium and Escherichia coli from a Chinese Women’s and Children’s HospitalIntravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia – a matched case–control study in neonatesBioavailability Enhancement of Polymyxin B With Novel Drug Delivery: Development and Optimization Using Quality-by-Design ApproachThe rise and spread of mcr plasmid-mediated polymyxin resistanceA Review of the Clinical Pharmacokinetics of Polymyxin BMolecular Mechanisms of Neurotoxicity Induced by Polymyxins and ChemopreventionHistory, Chemistry and Antibacterial SpectrumInactivation of the arn operon and loss of aminoarabinose on lipopolysaccharide as the cause of susceptibility to colistin in an atypical clinical isolate of proteus vulgarisPopulation Pharmacokinetics of Polymyxin B in Acutely Ill Adult PatientsSevere Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin BColistin-induced myasthenic syndrome in a patient with end-stage renal diseaseComplications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugsIllustrative examples of probable transfer of resistance determinants from food animals to humans: Streptothricins, glycopeptides, and colistinIntravenous polymyxins: Revival with puzzlePharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants DrugsThe safety of polymyxin antibioticsNeurotoxicity with Antimicrobials in the Elderly: A ReviewPolymyxins as Novel and Safe Mucosal Adjuvants to Induce Humoral Immune Responses in MiceNephrotoxicity and Efficacy Assessment of Polymyxin Use in 92 Transplant PatientsOutcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart reviewNeurotoxic effects associated with antibiotic use: management considerationsSystemic colistin use in children without cystic fibrosis: a systematic review of the literaturePolymyxins RevisitedColistin and Polymyxin B in Critical CareCombination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic FibrosisAnti-Infective DrugsThe Neurotoxicity of Antibacterial AgentsSHARON R. SNAVELY, M.D., GLENN R. HODGES, M.D.STRUCTURE SIDE-EFFECT SORTING OF DRUGS.Myopathy caused by polymyxin E: functional disorder of the cell membraneUntoward Effects of Antimicrobial Agents on Major Organ SystemsSusceptibility of 1,500 Isolates of Pseudomonas aeruginosa to Gentamicin, Carbenicillin, Colistin, and Polymyxin BHypocalcemia—a complication of childhood leukemiaDrug-induced neurologic disorders in childhoodThe in vitro Activity of several Antibiotics against Pseudomonas of Bovine udder OriginRecovery from Colistimethate NephrotoxicityRUSSELL E. RANDALL JR., M.D., F.A.C.P., GEORGE S. BRIDI, M.D., JOHN G. SETTER, M.D., NEWTON C. BRACKETT JR., M.D.Colistin and Sodium ColistimethateColistimethate OverdosageAdverse Effects of Sodium Colistimethate Manifestations and Specific Reaction Rates During 317 Courses of TherapyJAN KOCH-WESER, M.D., VICTOR W. SIDEL, M.D., ELIZABETH B. FEDERMAN, R.N., PAULA KANAREK, M.A., DIANA C. FINER, B.A., ANN E. EATON, M.Ed.Respiratory Infections and Antimicrobial TherapyCombined therapy with cephalothin, kanamycin and colistin in patients with presumed bacteremiaPeritoneal dialysis in colistin intoxication: Report of a caseUrinary Excretion of Polymyxin B Sulfate and Sodium Colistimethate in DogsCOLISTIN NEPHROTOXICITY: REPORT OF A CASE WITH LIGHT AND ELECTRON MICROSCOPIC STUDIES1The Effects of Renal Impairment, Peritoneal Dialysis, and Hemodialysis on Serum Sodium Colistimethate LevelsNORMA J. GOODWIN, M.D., ELI A. FRIEDMAN, M.D.Polymyxins, Colistin, Bacitracin, Ristocetin and VancomycinReversible Respiratory Paralysis Associated with Polymyxin TherapyLARRY A LINDESMITH, M.D., R. DIXIE BAINES JR., M.D., D. BOYD BIGELOW, M.D., THOMAS L. PETTY, M.D.Characteristics of Nonbacteremic Pseudomonas PneumoniaJAMES R. TILLOTSON, M.D., A. MARTIN LERNER, M.D., F.A.C.P.A Guide to Use of Antibiotics in Patients with Renal Disease A Table of Recommended Doses and Factors Governing Serum LevelsCALVIN M. KUNIN, M.D., F.A.C.P.Removal and Absorption of Antibiotics in Patients with Renal Failure Undergoing Peritoneal Dialysis Tetracycline, Chloramphenicol, Kanamycin, and ColistimethatePAUL A. GREENBERG, M.D., JAY P. SANFORD, M.D.1 Polypeptide Antibiotics of Medicinal InterestCOLISTIN IN PSEUDOMONAS PYOCYANEA INFECTIONS AND ITS EFFECT ON RENAL FUNCTIONAn unusual case of neuromuscular blockade seen with therapeutic blood levels of colistin methanesulfonate (Coly-Mycin)Treatment of Pseudomonas Keratitis in Humans*The Therapeutic Success and Nephrotoxicity of Colistin in Acute and Chronic Nephropathies with Impaired Renal FunctionSODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINSComplications associated with antibiotic therapyPolymyxin B and ColistinNewer Antimicrobial Agents Having Current or Potential Clinical ApplicationSerum Concentrations of Colistin in Patients with Normal and Impaired Renal Function 1 August 1962Volume 57, Issue 2_Part_1Page: 214-229KeywordsCareers in researchEscherichia coliKlebsiellaPneumoniaPseudomonasPseudomonas aeruginosaPseudomonas infectionsSepsisUrinary tract infections Issue Published: 1 August 1962 PDF DownloadLoading ...